UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Assessment of the Efficacy and Safety of Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia

American journal of nephrology, 2007-01, Vol.27 (5), p.447-457

2007

Volltextzugriff (PDF)

Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare open-label trial (VOLT)

Clinical therapeutics, 2006-11, Vol.28 (11), p.1935-1946

2006

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Solifenacin in Patients With Renal Insufficiency

Journal of Pharmacological Sciences, 2007, Vol.103(1), pp.67-74

2007

Volltextzugriff (PDF)

Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder

Current therapeutic research, 2009-12, Vol.70 (6), p.405-420

2009

Volltextzugriff (PDF)

PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUM-COMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN U.S. SUBJECTS

The American journal of gastroenterology, 2022-07, Vol.117 (7), p.1158-1161

2022

Volltextzugriff (PDF)

Sa1373 HELICOBACTER PYLORI ERADICATION RATES WITH VONOPRAZAN: SUBGROUP ANALYSIS FROM THE PHASE 3 PHALCON HP TRIAL

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-378-S-378

2023

Volltextzugriff (PDF)

Mo1281 COMPARISON OF LOCAL INVESTIGATOR-REPORTED VS CENTRALLY ADJUDICATED LOS ANGELES GRADES OF EROSIVE ESOPHAGITIS IN PATIENTS SCREENED FOR PARTICIPATION IN A RANDOMIZED TRIAL

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1011-S-1012

2024

Volltextzugriff (PDF)

Su1205: A CLINICAL DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF VONOPRAZAN ON THE PHARMACOKINETICS OF MIDAZOLAM

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-545-S-545

2022

Volltextzugriff (PDF)

Su1202: PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUMCOMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN HEALTHY U.S. SUBJECTS

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-543-S-544

2022

Volltextzugriff (PDF)

S524 Bioequivalence of Vonoprazan Sprinkle Capsule and Vonoprazan Tablet in Healthy Subjects

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S380-S381

2023

Volltextzugriff (PDF)

Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe

The American journal of gastroenterology, 2023-02, Vol.118 (2), p.269-275

2023

Volltextzugriff (PDF)

864 VONOPRAZAN FOR THE TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-198-S-198

2024

Volltextzugriff (PDF)

Su1203: NOVEL APPROACH TO EVALUATE THE IMPACT OF MODERATE AND STRONG CYP3A INDUCERS ON VONOPRAZAN EXPOSURE

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-544-S-544

2022

Volltextzugriff (PDF)

Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial

Clinical gastroenterology and hepatology, 2024-05

2024

Volltextzugriff (PDF)

Response to Graham

The American journal of gastroenterology, 2022-11, Vol.117 (11), p.1882-1883

2022

Volltextzugriff (PDF)

S390 Efficacy and Safety of On-Demand Vonoprazan versus Placebo in the Treatment of Heartburn in Symptomatic Nonerosive Reflux Disease (NERD) Patients: A Phase 2 Randomized Controlled Trial

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e272-e273

2022

Volltextzugriff (PDF)

S1387 A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race and Disease Status on Exposure

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S636-S637

2021

Volltextzugriff (PDF)

S1382 Vonoprazan Dual and Triple Therapy for Helicobacter pylori Eradication

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S634-S634

2021

Volltextzugriff (PDF)

S1449 Helicobacter pylori Resistance Rates in the U.S. and Europe: Data From the PHALCON-HP Study

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S665-S665

2021

Volltextzugriff (PDF)

YM905 Safely and Effectively Treats Symptoms of Overactive Bladder

Obstetrics and gynecology (New York. 1953), 2003-04, Vol.101 (Supplement), p.116

2003

Volltextzugriff (PDF)

CONIVAPTAN, A NOVEL V1A/V2 ANTAGONIST, INCREASED SERUM SODIUM AND EFFECTIVE WATER CLEARANCE IN HYPONATREMIA CLINICAL TRIALS: 590

Critical care medicine, 2004-12, Vol.32 (Supplement), p.A166

2004

Volltextzugriff (PDF)

CONIVAPTAN FOR THE TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS: RESULTS FROM AN OPEN-LABEL STUDY: 242

Critical care medicine, 2006-12, Vol.34, p.A64

2006

Volltextzugriff (PDF)

Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes

Current medical research and opinion, 2007-04, Vol.23 (4), p.821-831

2007

Volltextzugriff (PDF)

CONIVAPTAN, A NOVEL ARGININE VASOPRESSIN ANTAGONIST, PRODUCED AQUARESIS AND INCREASED SERUM SODIUM CONCENTRATION IN PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA: 234-T

Critical care medicine, 2005-12, Vol.33, p.A170

2005

Volltextzugriff (PDF)

Evaluating the efficacy and safety of the novel vasopressin V1A- and V2-receptor antagonist conivaptan for the treatment of acute decompensated chronic heart failure: study protocol

Journal of cardiac failure, 2004-08, Vol.10 (4), p.S85-S85

2004

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(33)

Sprache

Englisch
(32)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Assessment of the Efficacy and Safety of Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia

Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare open-label trial (VOLT)

Pharmacokinetics, Safety, and Tolerability of Solifenacin in Patients With Renal Insufficiency

Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder

PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUM-COMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN U.S. SUBJECTS

Sa1373 HELICOBACTER PYLORI ERADICATION RATES WITH VONOPRAZAN: SUBGROUP ANALYSIS FROM THE PHASE 3 PHALCON HP TRIAL

Mo1281 COMPARISON OF LOCAL INVESTIGATOR-REPORTED VS CENTRALLY ADJUDICATED LOS ANGELES GRADES OF EROSIVE ESOPHAGITIS IN PATIENTS SCREENED FOR PARTICIPATION IN A RANDOMIZED TRIAL

Su1205: A CLINICAL DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF VONOPRAZAN ON THE PHARMACOKINETICS OF MIDAZOLAM

Su1202: PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUMCOMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN HEALTHY U.S. SUBJECTS

S524 Bioequivalence of Vonoprazan Sprinkle Capsule and Vonoprazan Tablet in Healthy Subjects

Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe

864 VONOPRAZAN FOR THE TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL

Su1203: NOVEL APPROACH TO EVALUATE THE IMPACT OF MODERATE AND STRONG CYP3A INDUCERS ON VONOPRAZAN EXPOSURE

Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial

Response to Graham

S390 Efficacy and Safety of On-Demand Vonoprazan versus Placebo in the Treatment of Heartburn in Symptomatic Nonerosive Reflux Disease (NERD) Patients: A Phase 2 Randomized Controlled Trial

S1387 A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race and Disease Status on Exposure

S1382 Vonoprazan Dual and Triple Therapy for Helicobacter pylori Eradication

S1449 Helicobacter pylori Resistance Rates in the U.S. and Europe: Data From the PHALCON-HP Study

YM905 Safely and Effectively Treats Symptoms of Overactive Bladder

CONIVAPTAN, A NOVEL V1A/V2 ANTAGONIST, INCREASED SERUM SODIUM AND EFFECTIVE WATER CLEARANCE IN HYPONATREMIA CLINICAL TRIALS: 590

CONIVAPTAN FOR THE TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS: RESULTS FROM AN OPEN-LABEL STUDY: 242

Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes

CONIVAPTAN, A NOVEL ARGININE VASOPRESSIN ANTAGONIST, PRODUCED AQUARESIS AND INCREASED SERUM SODIUM CONCENTRATION IN PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA: 234-T

Evaluating the efficacy and safety of the novel vasopressin V1A- and V2-receptor antagonist conivaptan for the treatment of acute decompensated chronic heart failure: study protocol

Aktive Filter

Suchergebnisse filtern